HC Wainwright & Co. Initiates Coverage On Hoth Therapeutics with Buy Rating, Announces Price Target of $4
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has initiated coverage on Hoth Therapeutics (NASDAQ:HOTH) with a Buy rating and set a price target of $4.

February 05, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. initiated coverage on Hoth Therapeutics with a Buy rating and a price target of $4.
The initiation of coverage by a reputable analyst firm like HC Wainwright & Co. with a Buy rating and a specific price target can be a positive signal to the market, potentially leading to increased investor interest and a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100